An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)
Latest Information Update: 14 May 2024
At a glance
- Drugs Immune globulin (Primary)
- Indications Agammaglobulinaemia; Immunodeficiency disorders; Type 1 hyper-IgM immunodeficiency syndrome; X-linked genetic disorders
- Focus Pharmacokinetics
- Sponsors ADMA Biologics
- 09 May 2024 According to a ADMA Biologics media release, this trial may provide label expansion opportunities
- 13 Sep 2022 Status changed from not yet recruiting to recruiting.
- 25 Aug 2022 Planned initiation date changed from 1 Mar 2022 to 1 Sep 2022.